Summit Therapeutics Inc. — Director's Dealing 2020

Nov 26, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2020-11-23

Reporting Person: Powell David Jonathan (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-23	Common Stock	M	6987	$1.92	Acquired	6987	Direct
2020-11-23	Common Stock	S	6987	$4.40	Disposed	0	Direct
2020-11-24	Common Stock	M	11374	$1.92	Acquired	11374	Direct
2020-11-24	Common Stock	S	11374	$4.21	Disposed	0	Direct
2020-11-25	Common Stock	M	12070	$1.92	Acquired	12070	Direct
2020-11-25	Common Stock	S	12070	$4.32	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-23	Stock Option (right to buy)	$1.92	X	6987	Disposed	2028-10-19	Common Stock (6987)	Direct
2020-11-24	Stock Option (right to buy)	$1.92	X	11374	Disposed	2028-10-19	Common Stock (11374)	Direct
2020-11-25	Stock Option (right to buy)	$1.92	X	12070	Disposed	2028-10-19	Common Stock (12070)	Direct

Footnotes

F1: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices.

F2: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.41 to $4.40. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.

F3: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.24 to $4.20. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.

F4: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.40 to $4.21. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.

F5: The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date.